The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Apellis Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $67.31 and fluctuated between $68.57 as its day high and $66.48 as its day low. The current market capitalization of Apellis Pharmaceuticals Inc is $7.98B. A total of 0.82 million shares were traded on the day, compared to an average of 2.22M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, APLS has seen 3 BUY and 2 SELL insider trades, representing the acquisition of 63,744 and the disposition of 13,250 shares. Over the last 12 months, there were 63 BUYs and 81 SELLs from insiders. Insiders purchased 2,537,224 shares during that period but sold 1,851,391.
In the most recent transaction, Eisele Jeffrey sold 971 shares of APLS for 65.53 per share on Jan 30. After the transaction, the Chief Development Officer now owns 57,208 company shares. In a previous transaction on Jan 30, Lewis Karen sold 883 shares at 65.53 per share. APLS shares that Chief People Officer owns now total 46,387.
Among the insiders who sold shares, Francois Cedric disposed of 2,843 shares on Jan 29 at a per-share price of $64.14. This resulted in the Chief Executive Officer holding 317,624 shares of APLS after the transaction. In another insider transaction, Watson David O. sold 906 shares at $64.14 per share on Jan 29. Company shares held by the General Counsel now total 104,171.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for APLS in the last 3 months, the mean price target is $78.06 with high estimates of $110.00 and low estimates of $49.00. In terms of 52-week highs and lows, APLS has a high of $94.75 and a low of $19.83.
As of this writing, APLS has an earnings estimate of -$0.71 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$1.09. The company reported an EPS of -$1.02 in the last quarter, which was 22.70% higher than expectations of -$1.32.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. APLS’s latest balance sheet shows that the firm has $700.55M in Cash & Short Term Investments as of fiscal 2021. There were $210.22M in debt and $131.85M in liabilities at the time. Its Book Value Per Share was $1.96, while its Total Shareholder’s Equity was $198.66M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for APLS is Buy with a score of 4.40.